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DQA1 and HLA-DQB1 genotyping were performed in seropositive
subjects and a gluten-free diet was prescribed.
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Study Highlights: What Is Current Knowledge: patients with symptoms, signs, or laboratory evidence sugges
disease.
Celiac disease is common in Caucasians with HLA-DQ2.5 in 95% and HLA-DQ8 in most other patients
HLA-DQ9.3, rare in Caucasians, can also confer risk by the presence of DQ9-restricted gluten-specific T
Celiac disease is considered uncommon in Chinese and their HLA-DQ distribution unknown.
What Is New Here
Serological screening for celiac disease revealed that celiac disease is present in adult patients with diarrhea-pr
China.
HLA-DQ9.3, common in China, but not HLA-DQ2.5/DQ8was found in 2 patients with histologic abnormalitie
III lesion and supported by positive serology.
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Abstract: Celiac disease (CD) is common in Caucasians, but thought
to be rare in Asians. Our aim was to determine the prevalence of CD in
Chinese patients with chronic diarrhea predominant irritable bowel
syndrome (IBS-D).
From July 2010 to August 2012, 395 adult patients with IBS-D and
363 age and sex-matched healthy controls were recruited in Zhongnan
Hospital of Wuhan University and Xiaogan Central Hospital in Hubei
province, central China. Patients with IBS-D were diagnosed according
to the Rome III criteria. Serum Immunoglobulin (IgA/IgG) anti-human
tissue transglutaminase (anti-htTG)-deamidated gliadin peptide (DGP)
antibodies were measured in a single ELISA (QUANTA Lite h-tTG/berg, PhD, Serva hD,
, and Bing Xia, MD, PhD
Seven IBS-D patients (7/395, 1.77%) and 2 healthy controls (2/363,
0.55%), were positive for anti-htTG/DGP antibodies. Of these 9 cases, 1
was lost to follow-up, 3 were suspected to have CD and 5 were
eventually diagnosed as CD with intestinal histological lesions classi-
fied as Marsh Type II in 2 and Type III in 3. Of these 5 diagnosed CD
patients, 4 (4/395, 1.01%) were from the IBS-D group and 1 (1/363,
0.28%) from the healthy control had asymptomatic CD. Two Type III
CD patients with relatively high titers in the serologic assay were
homozygous and heterozygous for haplotype HLA-DQA103-
DQB103:03 (HLA-DQ9.3), respectively.
In the present study, CD was present in 1.01% of patients with IBS-control group. We like to suggest that the
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s a new susceptibility factor for CD in
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China. Larger screening and genetic studies are needed in the
Chinese population of different regions.
(Medicine 94(42):e1779)
Abbreviations: anti-htTG = anti-human tissue transglutaminase,
BMI = body mass index, CD = celiac disease, DGP = deamidated
gliadin peptide, DNA = deoxyribonucleic acid, ELISA = enzyme-
linked immunosorbent assay, GFD = gluten-free diet, HLA =
human leukocyte antigen, IBS = irritable bowel syndrome, IBS-D =
diarrhea-predominant irritable bowel syndrome, IEL =
intraepithelial lymphocyte, Ig = immunoglobulin, NCGS =
nonceliac gluten sensitivity, NSAID = nonsteroidal anti-
inflammatory drug, SD = standard deviation, SPTs/sIgE = skin
prick tests/specific immunoglobulin E, tTG2 = tissue
transglutaminase-2.
INTRODUCTION
C eliac disease (CD) is one of the gluten-related disordersincluding also nonceliac gluten sensitivity (NCGS) and
wheat allergy. CD is characterized by chronic mucosal inflam-
mation with infiltration of intraepithelial lymphocytes (IELs) in
the epithelium and plasma cells in the lamina propria, with crypt
hyperplasia and villous atrophy primarily in the upper small
intestine. The classical form of CD presents with symptoms and
signs of malabsorption such as chronic diarrhea, bloating,
weight loss, and abdominal pain but more recent clinically
silent nonclassical presentations in adults include iron-
deficiency anemia, osteoporosis, gastroesophageal reflux, con-
stipation, weight loss, neurologic symptoms, dermatitis herpe-
tiformis, hypoproteinemia, hypocalcemia, and elevated liver
enzyme levels.1 CD occurs in genetically susceptible individ-
uals exposed to dietary gluten. Approximately 90% of Cauca-
sian patients with CD are carriers of the human leukocyte
antigen (HLA)-DQ2.5 (DQA105-DQB102) heterodimers
encoded in cis (DQ2.5cis) or trans (DQ2.5trans) configuration and
the remainder carry either DQ8 (DQA103-DQB103:02), HLA-
DQ2.2 (DQA102-DQB102) heterodimers, or HLA-DQA105 only.
These HLA-DQ gene variants at the major histocompatibility complex
on chromosome 6p21.3 are present in 30% to 43% of the general
European population and explain 40% of the disease heritability,
whereas large genome-wide association studies have brought the num-
ber of non-HLA loci each contributing only a small risk to 39 explaining
14%, at present leaving 46% as ‘‘missing heritability’’.2 After a strict
gluten-free diet (GFD), the clinical symptoms and histological features
in CD patients improve in the great majority of patients.3,4
CD is an inflammatory autoimmune disease that affects
genetically predisposed individuals. It is triggered by the inges-
tion of gluten and other related proteins in barley, rye, and
possibly oats. The interaction of genetic and environmental
factors leads to loss of gluten tolerance and the development of
intestinal lesions characterized by increased number of lympho-
cytes in the epithelium and lamina propria, destruction of the
villi, alteration of epithelial cells, and mucosal remodeling with
the presence of auto-antibodies to the enzyme tissue transglu-
taminase-2 (tTG2). The lesion and inflammatory bowel changes
resolve when gluten is removed from the diet.5
In Caucasians the average prevalence is estimated to be
about 1% to 2% according to several epidemiological studies
using specific serological tests, evaluated by different methods
and markers.1 The prevalence in the countries of Northern
Wang et alEurope is slightly higher than the prevalence in the Mediterra-
nean. The Scandinavian countries, the United Kingdom, and
Ireland have shown a prevalence ranging from 1% to 2.5%.6
2 | www.md-journal.comThe average prevalence of CD in the United States is very
similar to the one observed in Europe.7 In the last years, a
greater awareness of CD and a more active search through
information campaigns and the dissemination of knowledge by
patients associations and internet active groups have contrib-
uted to a higher prevalence. Despite the lack of data, the
prevalence in Asian populations including Chinese was pre-
dicted to be low, due to the rice-based staple diets.8 The
knowledge on CD in China has started in recent years, though
no formal epidemiological studies have been performed yet.9,10
These reports are of great importance since they confirmed the
occurrence of CD in China.
Irritable bowel syndrome (IBS) is a chronic condition
characterized by abdominal discomfort or pain and altered
bowel habit. The prevalence of IBS in Europe and North
America is estimated to be 10% to 15% based on the Rome
II and III criteria, and in the Asia–Pacific region the prevalence
is somewhat lower (2.9% to 15.6%) but is increasing,11 particu-
larly in countries with developing economies.12 A small meta-
analysis revealed that the prevalence of biopsy-proven CD in
cases meeting diagnostic criteria for IBS is more than 4-fold
higher than in controls without IBS.13
The availability of highly sensitive and specific serologic
assays for CD has led to increased recognition that the disease is
more common than assumed. Sugai et al14,15 and Hogen Esch
et al16 reported that the IgA/IgG human-tTG/DGP enzyme-
linked immunosorbent assay (ELISA) is one of the most
sensitive screening tests for CD. Using an h-tTG/DGP com-
bined ELISA, we carried out a study of serological screening for
CD in adult Han Chinese patients with chronic diarrhea pre-
dominant IBS (IBS-D) that is the most frequent form of IBS and
represents a high risk group to suffer from CD and healthy
individuals. In addition, in serologic positive subjects we
performed endoscopic and biopsy examinations, HLA-DQ
genotyping, to estimate the prevalence of CD in central China.
METHODS
Recruitment of Patients With Chronic Diarrhea
and Healthy Controls
Between July 2010 and August 2012, 417 consecutive
patients diagnosed with IBS-D in Zhongnan Hospital of Wuhan
University in Wuhan city and Xiaogan Central Hospital near
Wuhan, both in Hubei Province, central China were recruited.
All the patients were Han Chinese referred by doctors from the
departments of Gastroenterology of these hospitals. All patients
completed a questionnaire, which comprised sex, date of birth,
height, weight, education status, dietary habit, staple food,
current clinical manifestations, especially gastrointestinal
symptoms and signs including detailed information of diarrhea,
previous and current medications, personal and family medical
history, etc. Twenty-two subjects were excluded in accordance
with the exclusion criteria given below, and no significant
differences exist in age, sex, body mass index (BMI), and
indications for referral between those included in and those
excluded from the study. All patients were on a normal gluten
containing diet consisting of wheat, and oat at the time of
inclusion. A total of 183 men and 212 women, mean age
48.37 11.6, and BMI 21.6 4.1 (kg/m2, mean SD) were
included. The inclusion criteria were age greater than 18 but
less than 80 years old; diagnosis of IBS-D according to the
Medicine  Volume 94, Number 42, October 2015Rome III criteria; and a signed consent form. Patients were
excluded if they took NSAIDs, suffered from intestinal tuber-
culosis or antibiotic-associated diarrhea 4 weeks prior to the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
patients had improvement of clinical symptoms including
chronic diarrhea, abdominal pain, and decreased serum anti-
body level compared with pre-GFD.
Individuals positive for IgA/IgG 
anti-htTG/DGP antibodies
Gluten-free diet and nutritional 
education
Periodic assessment of symptoms, 
diet and serology
Serology 
abnormal
Yes No
Reinforce 
adherence
Symptoms 
present
No
Yes
Evaluate other causes of symptoms and study; were diagnosed with villous adenomas, microscopic
colitis, or inflammatory bowel disease; had a history of gas-
tro-intestinal cancer; were positive for antibody to human
immunodeficiency virus, hepatitis B antigen, or hepatitis C
virus; or were syringe drug users or cocaine inhalers.
In addition, 363 age and sex-matched healthy controls
taking the annual routine health examinations in Zhongnan
Hospital of Wuhan University and Xiaogan Central Hospital
were recruited in this study. Healthy individuals did not fill out
the above-mentioned questionnaire but they were confirmed to
be normal in the examination during the period of the study and
were excluded when chronic diarrhea or the same exclusion
items used for IBS-D patients were apparent. A total of 173 men
and 190 women, mean age 47.47 15.18 (years), and BMI
24.13 3.95 (kg/m2, meanSD) were included. BMI of
healthy controls was significantly higher than of IBS-D patients
(P< 0.001). The study protocol was approved by the Medical
Ethics Committee of Zhongnan Hospital of Wuhan University.
All included subjects signed the consent form for the project.
Diagnostic Criteria for Celiac Disease
CD was diagnosed when the anti-htTG/DGP antibodies
test was positive, a Marsh II or III abnormality was found in the
small intestinal biopsy specimen, and an objective response to a
GFD was obtained. The Marsh classification was used for
histological grading of the duodenal biopsy specimens.17
H-tTG/DGP Enzyme-Linked Immunosorbent
Assay
Approximate 3mL venous blood was obtained from each
individual, and then centrifuged at 3000 rpm for 10 minutes.
The serum samples were stored at 808C until use. All serum
samples were subjected to IgA/IgG anti-htTG/DGP ELISA
(QUANTA Lite, h-tTG/DGP ELISA; number 704575, Inova
Diagnostics Inc., San Diego, CA), which is a solid phase
enzyme immunoassay for the quantitative detection of IgA/
IgG antibodies to synthetic DGP and the native h-tTG. In
accordance with recommendations by the manufacturer, serum
samples were defined to be positive for anti-htTG/DGP ELISA
antibodies when the measured values were 20 Units or above.
HLA-DQ Typing
Genomic DNA of seven (No. 1, No. 2, No. 3, No. 4, No. 5,
No. 8, No. 9) serologic positive subjects was extracted from
250mL serum using the EasyMAGNucliSens extraction system
(BioMe´rieux Benelux BV, Zaltbommel, The Netherlands).
2mL NucliSens lysis buffer was added to the serum and
incubated for 10minutes at room temperature. The mixture
was then added to the EasyMAG vessel and 50mL of magnetic
silica was subsequently added. The DNA was extracted on the
EasyMAG machine (BioMe´rieux Benelux BV, Zaltbommel,
The Netherlands) using the Generic 2.0.1 program. Elution
was performed in 25mL NucliSens Extraction buffer 3.18
EDTA-anticoagulated peripheral blood nucleated cells of the
other 2 serologic positive subjects (No. 6 and No. 7) were
available for extraction of genomic DNA. For HLA-DQA1 and
HLA-DQB1 genotyping, polymerase chain reaction-amplified
exon 2 amplicons were generated for low- to medium resolution
typing in a combined, single-stranded conformation poly-
morphism–heteroduplex assay by a semiautomated electropho-
Medicine  Volume 94, Number 42, October 2015resis and gel-staining method on the PhastSystem (Amersham
Pharmacia Biotech, Uppsala, Sweden). This method has been
validated by using a panel of reference DNA against the Dynall
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Allset sequence-specific primers high-resolution typing kits
(Dynal A.S., Oslo, Norway).19,20
Endoscopic and Histological Assessments and
Intraepithelial Lymphocyte Counting in Patients
Positive for Anti-htTG/DGP ELISA Antibodies
Patients positive for IgA/IgG anti-htTG/DGP antibodies
were asked to accept endoscopic examination of the duodenum
and biopsies. At the endoscopy, 4 to 6 biopsies were obtained
from the descendent duodenum at different levels distal to the
papilla. The biopsies were fixed with 10% buffered formalin,
embedded in paraffin blocks, and stainedwith hematoxylin and
eosin. Two experienced pathologists blindly evaluated the
histologic pattern under the microscope and assigned a Marsh
classification to the biopsy findings. Type 0 indicates a normal
small intestinal architecture sufficient to exclude celiac dis-
ease, type I (infiltrative) is characterized by increased IELs,
type II (hyperplastic) indicates also crypt hyperplasia, and an
additional partial, subtotal, or total villous atrophy character-
izes the type III (destructive) lesion.21 Moreover, all histologi-
cal sections were examined by light microscopy (400
magnification), and the numbers of epithelial cells and IELs
in a randomly chosen, uninterrupted length of the villous
epithelium (>500 cells) were counted. The average number
of IELs within 100 intestinal epithelial cells was calculated,
and 40 IELs/100 epithelium cells was defined as the upper limit
of the normal.22–24
Treatment of a Gluten-Free Diet for Patients
Positive for Anti-htTG/DGP IgA/IgG
Patients positive for anti-htTG/DGP IgA/IgG were asked
to receive GFD treatment. During a GFD, it was advised to
avoid all gluten-containing food. Patients were monitored by
periodic hospital visits for assessment of symptoms, physical
examinations, and adherence to the GFD (Figure 1). Positive
response to GFD treatment was defined when strictly compliant
Serological Screening for Celiac Disease in IBS-Dconsider re-biopsy
FIGURE 1. Treatment and monitoring of patients positive for IgA/
IgG anti-htTG/DGP antibodies.
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Evaluation of Clinical Symptoms
The criteria for evaluating clinical manifestations was
based on 4 symptoms: abdominal pain; abdominal discomfort
(eg, bloating, abnormal stress sense); change in bowel habits;
change in bowel traits. The severity score for each symptomwas
evaluated as: 0, asymptomatic; 1, mild (no influence on daily
life or sleep); 2, moderate (obvious symptoms with mild
limitation of daily life); 3, severe (symptoms significantly affect
the daily life). The clinical symptoms were assessed before and
after GFD therapy and the total score (0–12) was calculated
according to the above rating standard.
Statistical Analysis
The overall prevalence was reported using relative fre-
quencies and percentages with the corresponding 95% confi-
dence interval (95% CI) on the basis of the binomial
distribution. Mean, standard deviations (SD), or median and
range were used as continuous statistics while evaluating using
Student t test. Frequency differences were compared using
Fisher exact test. Statistical significance was established at
the P value<0.05. All calculations were performed using SPSS
for Windows, version 17.0 (SPSS, Inc, Chicago, IL). Figures
were drawn using GRAPHPAD Prism 5.0 (GraphPad Software,
Inc, San Diego, CA).
RESULTS
Serum IgA/IgG Anti-htTG/DGP Antibodies
in IBS-D Patients and Healthy Controls
The values of cases positive for the IgA/IgG anti-htTG/
DGP antibodies are shown in Table 1 and Supplemental Digital
Content, http://links.lww.com/MD/A463 (see Figure, Supple-
mental Digital Content, http://links.lww.com/MD/A463 which
illustrates the serum IgA/IgG anti-htTG/DGP antibodies as
determined by ELISA in patients with IBS-D and healthy
controls, in relation to sex). There was no significant difference
between the values in males and females in both IBS-D patients
and healthy controls. Seven (1.77%) IBS-D patients and 2
(0.55%) healthy controls were positive for IgA/IgG anti-
htTG/DGP antibodies. However, this difference was not sig-
nificant (1.77% vs. 0.55%, P¼ 0.41). Two IBS-D patients (No.
6 and No. 7) had relatively high titers (50 Units) compared
with the other serologic screening test positive subjects.
Duodenal Biopsy and Histological Assessment
Table 1 shows features of the 9 IgA/IgG anti-htTG/DGP
positive subjects. Of these, 5 subjects (No. 1, No. 4, No. 6, No. 7,
and No.9) underwent upper endoscopy and duodenal biopsies
for histological assessment and showed increased numbers
(range: 47–61) of IELs per 100 epithelial cells. In addition,
subject No. 1 had enlargement of the crypts (Marsh II;
Figure 2A); subject No. 4 villous atrophy and cryptic hyper-
plasia (Marsh III; Figure 2B); subjects No. 6 and No. 7 villous
atrophy and cryptic hyperplasia (Marsh III; Figures 2C and D),
respectively; subject No. 9 enlargement of crypts (Marsh II;
Figure 2E).
Change in the IgA/IgG Anti-htTG/DGP Antibody
Levels and Clinical Responses in Positive Subjects
Wang et alFollowing Treatment With a Gluten-Free Diet
Among the 9 subjects positive for IgA/IgG anti-htTG/DGP
antibodies, all except 1 (No. 3) who was lost to follow-up were
4 | www.md-journal.comadvised to receive a GFD treatment. Of the 8 subjects, patients
No. 1, No. 2, No. 5, No. 6, No. 7, and No. 8 strictly followed the
GFD requirements for a median duration of 4.9 months,
whereas patients No. 4 and No. 9 refused a GFD. The changes
of serum IgA/IgG anti-h-tTG/DGP antibodies during follow-up
in months in these 6 subjects with GFD and the other 2 without
GFD are shown in Figure 3. The post-GFD clinical responses, as
well as the categories of the patients’ compliance with the GFD,
are demonstrated in Table 1. All the subjects refused to re-
undergo upper endoscopy.
HLA-DQ Genotyping
HLA-DQA1 and DQB1 genotypes of all subjects except
No. 2 were established (Table 2). Subject No. 8 was hetero-
zygous for the CD-associated haplotype HLA-DQA105-
DQB102 (DQ2.5cis). Subject No. 6 was homozygous and
subject No. 7 was heterozygous for the haplotype HLA-
DQA103-DQB103:03 (DQ9.3), and both were negative for
the CD-associated DQ2.5 and DQ8 (HLA-DQA103-
DQB103:02). Subject No. 4 was a heterozygous carrier of
HLA-DQA102:01-DQB102 (DQ2.2). Subjects No. 1 and
No. 9 were heterozygous for the haplotype HLA-DQA105-
DQB103:01 (DQ7.5) containing only half of DQ2.5 (ie, HLA-
DQA105) with subject No. 1 also containing half of DQ9.3 (ie,
heterozygous for HLA-DQB10303). Subjects No. 3 and No. 5
did not carry any of these allelic combinations mentioned in
either the cis or trans configuration.
Diagnosis of Patients With IBS-D and Healthy
Controls
Of 9 serological positive subjects, 5 (No. 1, No. 4, No. 6,
No. 7, and No. 9) presented with type II or type III intestinal
histological lesions were considered to suffer from celiac dis-
ease. One subject (No. 8) from the healthy control group was
considered to be a potential CD candidate, unfortunately the
control did not accept the possibility of taking a biopsy of the
small intestine. Two other subjects (No. 2, No. 5) were only
suspected to have CD in the absence of histologic evidence. The
last subject (No. 3) was lost to follow-up. Of note, 3 individuals
in IBS-D group who were negative for anti-htTG/DGP IgA/IgG,
complained of abdominal pain, diarrhea, bloating, or tiredness
after the ingestion of gluten-containing food in the question-
naire and the medical record, but they did undergo neither
gluten challenge nor GFD, neither skin prick tests/specific
immunoglobulin E (SPTs/sIgE) nor histological examination;
therefore, they were suspected to have gluten intolerance, either
nonceliac gluten sensitivity or wheat allergy. No other gluten-
related findings were observed in the control group due to lack
of further investigation.
DISCUSSION
The present study confirms that celiac disease exists in
patients with IBS and healthy subjects in the Han Chinese
population. With the traditional rice staple food gradually being
replaced by Western-style food containing a high content of
wheat8 CD appears to inevitably become a health problem in
China. Performance of the serological test in a clinical setting
depends on patient characteristics (eg, age, genetic predisposi-
tion, and IgA deficiency), pretest probability, stage of disease,
Medicine  Volume 94, Number 42, October 2015and ingested amounts of gluten. IgA deficiency in Chinese is
much lower than in Western populations.25,26 We used the IgA/
IgG human-tTG/DGP ELISA with a high sensitivity of 96.8%
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Wang et al Medicine  Volume 94, Number 42, October 2015and a specificity of 100.0% with a cut-off level of 20 Units
established in citizens from the United States.27 Although CD
appears to be much less common than in Western countries, the
serum IgA/IgG anti-htTG/DGP antibody values showed
statistical differences between the IBS-D group and the healthy
control group (8.19 2.36 vs. 6.75 3.11, P¼ 0.0001). Of
FIGURE 2. Histological assessment of duodenal biopsies of subject
magnification), and No. 9 (E) low (100) and high (200 magnnote, using the same composite antigen ELISA, Sugai et al
detected much higher antibody titers in Caucasian CD
patients.14 The total amount of wheat in the Chinese diet is
6 | www.md-journal.comprobably much less than in other countries. Unfortunately, we
have not quantified and registered the age of introduction of
gluten intake in our subjects. However, we think that these
values do not affect the diagnosis of CD, particularly when the
other diagnostic criteria such as duodenal biopsy specimen’s
histological assessment, clinical symptoms, and the response to
o. 1 (A), No. 4 (B), No. 6 (C), No.7 (D) low (40) and high (100
tion) are on the left and right respectively.GFD were observed.28 Among the 9 individuals suspected of
having CD on the ground of histological biopsy abnormalities, 2
of Table 1 (No. 4 and No. 9) were confirmed to have CD by
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 42, October 2015 Serological Screening for Celiac Disease in IBS-Dhistology, 3 (No. 1, No. 6, and No. 7) were confirmed to have
CD by both histology, 1 (No. 3) was lost to follow-up, and 3
(No. 2, No. 5, and No. 8) were suspected to have CD by response
to GFD but without histological evidence.
Duodenum and jejunal biopsy assessments have been the
gold standard diagnostic test for CD during the last 30 years. An
increase in the number of IELs is the first and most sensitive
index of the effects of CD.29 In the present study, 5 seropositive
subjects agreed to undergo upper endoscopy and to have
duodenal mucosa biopsies taken. Histological lesions (Type
II or Type III) marked the diagnosis of CD in all 5 cases.
We noted that in 1 healthy subject (No. 9) positive for anti-
htTG/DGP antibodies, the diagnostic duodenal biopsy histo-
logical assessment was Type II and this individual probably has
CD but is asymptomatic. Indeed, it has been reported that
although a broad spectrum of symptoms may be associated
with untreated CD, many patients, especially those presenting in
adulthood, have Marsh I histological abnormalities but often
anemia and osteoporosis.30–32 Also, long-term observation
indicates that the majority of these patients will eventually
develop typical histological lesions of CD at some time.33 Thus,
we suppose that the actual prevalence of CD in China may be
possibly even higher than our finding and that silent cases may
underestimate it as those individuals will not be screened.
The 2 healthy individuals with abnormal antibody levels
FIGURE 3. Changes of serum IgA/IgG anti-htTG/DGP antibodies
GFD. Subjects No. 1, No. 2, No. 5, No. 6, No. 7, and No. 8 wi
treatment of GFD for a median duration of 4.9 months (range 4.were asymptomatic, whereas from the 5 patients with IBS-D 1
had type 1 diabetes mellitus and 4 had associated signs and
symptoms, such as malnutrition in 1 and anemia in 4. In line
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.with studies in Western countries, our data further demonstrate
that CD is more common in patients with IBS-D diagnosed with
strict application of Rome III criteria, compared with the
general population. Our results and others in the literature
would suggest that routine screening for CD in patients with
symptoms of IBS is necessary, at least in patients who present
with gastrointestinal symptoms, including chronic diarrhea,
malabsorption, weight loss, and abdominal distention.
DQ2.5, DQ8, and DQ9.3 in the General
Population and the Study Population
The frequency of HLA-DRB103, uniquely carrying the
haplotype DQ2.5cis (HLA-DQA105-DQB102), is 4.1% in
the Han population of Wuhan, Hubei province in accordance
with a range between 3% and 5% on mainland China.34,35 Since
the frequency of HLA-DQB102 in Han Chinese from Hubei is
10.7%, the frequency of DQ2.5trans (HLA-DQA105/
DQB102) amounts 6.6%. Therefore, with a frequency between
4.1% and 10.7% DQ2.5 is common in the general population
under study.35 The frequency of HLA-DQB10302, mainly
present in China on haplotypes with HLA-DRB104-
DQA103, is 6.2% in the Han population of Wuhan in accord-
ance with a range between 4.5% and 5.6% in other regions of
mainland China, HLA-DQA103:02/DQB103:03:02 is
strongly associated with susceptibility to childhood-onset ocu-
ing follow-up in subjects with gluten-free diet (GFD) and without
nitially positive for IgA/IgG anti-htTG/DGP antibodies, following
.0 mo). No. 4 and No. 9 had no gluten restrictions.lar myasthenia gravis in Southern Han Chinese.36,37
In our study, 1 out of 9 subjects (No. 8) was heterozygous
for the CD-associated HLA-DQ2.5cis. No subject was positive
www.md-journal.com | 7
in Caucasians, is probably a susceptibility factor for CD in
TABLE 2. HLA-DQA1 and HLA-DQB1 Genotypes As Well As Inferred HLA-DQA1-DQB1 Diplotypes in Seropositive Subjects
No. of Subject HLA-DQA1 Genotype HLA-DQB1 Genotype HLA-DQA1–DQB1 Diplotype
1 02/05 03:01/03:03 DQ7.5/DQ9.2
2 NT NT NT
3 01:02/03 04/06:04 DQ4.3/DQ6.4
4 01:01/02:01 02/05:01 DQ2.2/DQ5.1
5 01:03/04 or 06:01 03:01/06:03 DQ6.3/DQ7.4 or 7.6
6 03/03 03:03/03:03 DQ9.3/DQ9.3
7 03/03 03:03/04 DQ4.3/DQ9.3
8 01:03/05 02/06:01 DQ2.5cis/DQ6.1
e an
Wang et al Medicine  Volume 94, Number 42, October 2015for HLA-DQ8. Subject No. 6 is homozygous for HLA-DQ9.3
(HLA-DQA103-DQB10303) and No.7 is heterozygous for
HLA-DQ9.3. HLA-DQB10303 has a frequency of 18.4% in
Hubei and is present on both DQ9.2 (HLA-DQA102-
DQB10303) and DQ9.3 haplotypes. The frequency of
HLA-DQ9.3 is high in mainland China, ranging from 13.8%
to 21.9%.37 Islet autoantibodies are associated with HLA-DQ
genotypes in Han Chinese patients with type 1 diabetes and their
relatives.38 HLA-DQ9.3 carries aspartate at DQb57 but is
otherwise identical to HLA-DQ8 in the peptide binding cleft.
Recently, a dominant DQ9-restricted gluten epitope (DQ8-glut-
1) previously identified in DQ8-positive CD patients revealed a
strong T-cell response and sustained strong binding to DQ9.3
demonstrating DQ9 is a susceptibility factor for CD.39 We also
noticed that both subjects No. 6 and No. 7 had relatively high
titers (52.2 and 52.9 Units, respectively) in the sensitive ser-
ologic screening test when compared with the other CD patients
with levels just above the cut-off value of 20 Units. Thus, we
hypothesize that in addition to a lower gluten intake variations
in genetic background across different populations, such as the
haplotype HLA-DQA103-DQB103:03 (DQ9.3) (with a fre-
quency less than 1% in American whites) determines a lower
humoral response. HLA-DQ9.3 might very well be a new
susceptibility factor for CD in China.
In our study, 5 subjects were finally diagnosed with CD
and 3 were diagnosed as suspected CD. As for the HLA-DQ2.5/
DQ8 status, subject No. 4 is associated with DQ2.2, subject’s
No. 1 and No. 9 with DQX.5, and both No. 3 and No. 5 patients
have HLA status of DQX.x, all of which obviously indicate to
observe probably big differences in CD-associated genotype
background between Central Han Chinese and white Caucasian
patients. We noticed that in our research subject No. 8, who
belongs to the healthy control group, is HLA-DQ2.5 positive,
was without appearance of clinical symptoms, and had high
antibody level that decreased after GFD. Thus very like he has
CD in an asymptomatic form and a close follow-up is indicated.
There are some limitations in our study, such as the relatively
small number of patients and controls and the selection covering
2 large referral centers in the Hubei Province. Moreover, 4 out
of 9 seropositive individuals declined to undergo upper endo-
scopy and diagnostic biopsies taken and could therefore, at best,
be diagnosed as suspected CD.
Interestingly, in response to the questionnaire of our study
on CD, 3 of IBS-D patients who were negative for CD in
9 03/05
Diplotype is the haplotype pair in a subject. HLA¼ human leukocytthe serological marker test reported intestinal and/or extrain-
testinal symptoms after ingestion of gluten containing food.
This suggests that these patients were suffering from
8 | www.md-journal.comother gluten-related disorders, nonceliac gluten sensitivity,40,41
or wheat allergy.42 However, in our study neither double-
blind, placebo-controlled gluten challenge nor SPTs/sIgE was
performed, nor has the influence of ‘‘Fermentable Oligo-Di-
Monosaccharides and Polyols’’ (FODMAPs) in their diets been
studied. These aspects are certainly worth investigating in
future studies with our patients.40,41,43
Recently while this manuscript was in preparation Lu et al
described a series of Asian, mainly Chinese, patients with IBS
who were tested positive for IgA DGP, and improved on a
gluten exclusion diet but without celiac disease.44 A recent
study performed in Iran has demonstrated that many IBS
patients are gluten-sensitive, and their symptoms could be
adequately controlled with a gluten-free diet only. These
authors suggest that gluten sensitivity should be investigated
first, and then elimination of FODMAP might be considered in
nonresponders for whom a gluten-free diet proves to be inef-
fective in controlling the symptoms. This approach is interest-
ing to follow in future studies.45
In conclusion, the prevalence of celiac disease in patients
with IBS-D is 1.01% (4/395) and 0.28% (1/363) in the control
group. The haplotype HLA-DQA103-DQB103:03 (HLA-
DQ9.3), which is common in Chinese but has a low frequency
03:01/03:01 DQ7.3/DQ7.5
tigen, NT¼ not tested.China. Larger screening and genetic studies in different regions
are needed to confirm this finding.
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